Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 14.12 is 47% above its 5-year average of 9.63, near the high end of its 5-year range (6.82–14.12).
17.96% above its 12-month average of 11.97.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 4.23.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-16T22:30:34.479Z. Historical observations retain their original dates. Historical series through 2026-09-11.
EARNINGS PER SHARE (EPS)
14.12
EARNINGS PER SHARE (EPS) AVG TTM
11.97
EARNINGS PER SHARE (EPS) AVG 3Y
10.56
EARNINGS PER SHARE (EPS) AVG 5Y
9.63
EARNINGS PER SHARE (EPS) AVG 10Y
6.79
EARNINGS PER SHARE (EPS) AVG 15Y
5.16
EARNINGS PER SHARE (EPS) AVG 20Y
4.13
CURRENT VS TTM AVG
+17.96%
CURRENT VS 3Y AVG
+33.74%
CURRENT VS 5Y AVG
+46.60%
CURRENT VS 10Y AVG
+108.09%
CURRENT VS 15Y AVG
+173.81%
CURRENT VS 20Y AVG
+242.24%
IDEXX Laboratories, Inc.
Market Cap
$40.52B
Earnings Per Share (EPS)
14.12
TTM Avg
11.97
3Y Avg
10.56
5Y Avg
9.63
Market Cap
$43.41B
Earnings Per Share (EPS)
5.08
TTM Avg
4.52
3Y Avg
4.36
5Y Avg
3.96
Market Cap
$44.25B
Earnings Per Share (EPS)
8.06
TTM Avg
7.74
3Y Avg
7.17
5Y Avg
5.87
Market Cap
$44.87B
Earnings Per Share (EPS)
0.60
TTM Avg
-0.11
3Y Avg
-0.73
5Y Avg
-1.03
Market Cap
$46.18B
Earnings Per Share (EPS)
10.56
TTM Avg
9.94
3Y Avg
15.54
5Y Avg
18.41
Market Cap
$32.62B
Earnings Per Share (EPS)
-10.44
TTM Avg
-3.64
3Y Avg
-0.05
5Y Avg
0.88
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $40.52B | 14.12 | 11.97 | 10.56 | 9.63 |
| Agilent Technologies, Inc. (A)vs › | $43.41B | 5.08 | 4.52 | 4.36 | 3.96 |
| IQVIA Holdings Inc. (IQV)vs › | $44.25B | 8.06 | 7.74 | 7.17 | 5.87 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $44.87B | 0.60 | -0.11 | -0.73 | -1.03 |
| Humana Inc. (HUM)vs › | $46.18B | 10.56 | 9.94 | 15.54 | 18.41 |
| ResMed Inc. (RMD)vs › | $33.11B | 10.40 | 10.00 | 8.26 | 6.94 |
| DexCom, Inc. (DXCM)vs › | $32.96B | 2.53 | 1.80 | 1.48 | 1.30 |
| Centene Corp. (CNC)vs › | $32.62B | -10.44 | -3.64 | -0.05 | 0.88 |
| Alcon Inc. (ALC)vs › | $32.33B | 1.30 | 2.02 | 1.68 | 1.07 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $32.03B | 5.92 | 0.10 | -3.15 | -4.54 |
Trailing EPS (TTM)
$14.12
Forward EPS (Est.)
$14.77
P/E Ratio
36.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 13.17 |
| 2024-12-31 | 10.77 |
| 2023-12-31 | 10.17 |
| 2022-12-31 | 8.12 |
| 2021-12-31 | 8.74 |
| 2020-12-31 | 6.82 |
| 2019-12-31 | 4.97 |
| 2018-12-31 | 4.34 |
| 2017-12-31 | 3.00 |
| 2016-12-31 | 2.47 |
| 2015-12-31 | 2.07 |
| 2014-12-31 | 1.82 |
| 2013-12-31 | 1.77 |
| 2012-12-31 | 1.62 |
| 2011-12-31 | 1.43 |
| 2010-12-31 | 1.23 |
| 2009-12-31 | 1.04 |
| 2008-12-31 | 0.97 |
| 2007-12-31 | 0.77 |
| 2006-12-31 | 0.75 |
| 2005-12-31 | 0.60 |
| 2004-12-31 | 0.57 |
| 2003-12-31 | 0.42 |
| 2002-12-31 | 0.34 |
| 2001-12-31 | 0.28 |
| 2000-12-31 | 0.27 |
| 1999-12-31 | 0.21 |
| 1998-12-31 | -0.10 |
| 1997-12-31 | -0.14 |
| 1996-12-31 | 0.22 |
